Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine Profiles in Patients with Chronic Kidney Disease and Low Sexual Function.

American journal of physiology. Renal physiology·2026
Same author

Impact of Prior Adverse Pregnancy Outcome on Kidney Structure and Function in Kidney Donors.

Kidney360·2026
Same author

Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug Dosing.

Clinical pharmacology and therapeutics·2026
Same author

Kidney Stone Research in the Rochester Epidemiology Project.

Mayo Clinic proceedings·2026
Same author

Early Experience With Beta-Lactam Therapeutic Drug Monitoring in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program.

Open forum infectious diseases·2026
Same author

Is It Possible to Prevent Atrial Fibrillation After Cardiac Surgery, or Is It Inevitable?

Critical care medicine·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
09:09

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice

Published on: August 9, 2013

41.1K

SGLT2 Inhibitors and GLP-1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta-Analysis.

Erin F Barreto1, Yessie A Garcia-Nieves2, Evan C Johnson3

  • 1Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.

Pharmacotherapy
|April 8, 2026
PubMed
Summary
This summary is machine-generated.

Sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise in improving outcomes for acute kidney injury (AKI) patients. These medications were linked to reduced major adverse kidney events and mortality in a systematic review.

Keywords:
acute kidney injurychronic kidney diseasemajor adverse kidney eventsmedication reconciliationnephroprotective medications

More Related Videos

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

5.0K
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
03:13

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research

Published on: November 3, 2023

3.2K

Related Experiment Videos

Last Updated: May 24, 2026

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice
09:09

Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice

Published on: August 9, 2013

41.1K
A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
09:02

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

5.0K
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
03:13

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research

Published on: November 3, 2023

3.2K

Area of Science:

  • Nephrology
  • Pharmacology
  • Clinical Medicine

Background:

  • Sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established nephroprotective agents for chronic kidney disease (CKD).
  • The impact of SGLT2i and GLP-1 RAs on acute kidney injury (AKI) outcomes remains largely uncharacterized.

Purpose of the Study:

  • To systematically review and meta-analyze the effect of SGLT2i or GLP-1 RAs on clinical outcomes in adult patients experiencing AKI.
  • To estimate the association between SGLT2i/GLP-1 RA exposure and adverse kidney events, mortality, and kidney replacement therapy.

Main Methods:

  • Systematic search of Embase, MEDLINE, Scopus, Web of Science, and clinical trial registries up to July 3, 2025.
  • Inclusion of observational studies and clinical trials evaluating adult AKI patients exposed to SGLT2i or GLP-1 RAs versus non-exposed controls.
  • Random effects meta-analyses were conducted to pool outcome data.

Main Results:

  • Seven studies (N=432,048) met eligibility criteria, predominantly observational, with one randomized trial for SGLT2i.
  • Exposure to SGLT2i or GLP-1 RAs was associated with significantly lower odds of major adverse kidney events (MAKE) (OR 0.63) and all-cause mortality (OR 0.36).
  • SGLT2i therapy was associated with reduced odds of kidney replacement therapy (OR 0.61) in studies evaluating this outcome.

Conclusions:

  • Post-AKI exposure to SGLT2i or GLP-1 RAs, primarily evidenced in observational data, is associated with improved clinical outcomes.
  • These findings suggest a potential renoprotective role for SGLT2i and GLP-1 RAs in the context of AKI.
  • Further investigation through randomized clinical trials is warranted to confirm these promising associations.